Comparison
3 Methylglutaconic Aciduria C3696376 vs 17q11 2 Microduplication Syndrome C3495679
Clinical comparison between 3 Methylglutaconic Aciduria and 17q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria C3696376
A metabolic disorder causing abnormal acid buildup affecting multiple body systems including the brain. Severity varies widely among affected individuals. Care focuses on symptom management and metabolic support.
17q11 2 Microduplication Syndrome C3495679
A genetic disorder caused by duplication of a segment on chromosome 17. Individuals may have developmental delays, behavioral concerns, and physical features. Treatment focuses on early intervention.
6 comparison axes
Onset
3 Methylglutaconic Aciduria C3696376
0-10
17q11 2 Microduplication Syndrome C3495679
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria C3696376
severe
17q11 2 Microduplication Syndrome C3495679
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria C3696376
Chronic
17q11 2 Microduplication Syndrome C3495679
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria C3696376
No
17q11 2 Microduplication Syndrome C3495679
No
Different transmission
Body System
3 Methylglutaconic Aciduria C3696376
metabolic
17q11 2 Microduplication Syndrome C3495679
congenital
Same/different system
Category
3 Methylglutaconic Aciduria C3696376
metabolic
17q11 2 Microduplication Syndrome C3495679
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-C3696376 and 17q11-2-microduplication-syndrome-C3495679 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria C3696376 | 17q11 2 Microduplication Syndrome C3495679 | Discriminating power |
|---|---|---|---|
| Metabolic decompensation | May include episodes of acidosis or neurologic change; severity varies widely. | Not a typical metabolic crisis pattern based on available description. | High |
| Developmental profile | Neurologic involvement can occur, but course is not uniform. | Developmental delay and behavioral concerns are commonly described. | Moderate |
| Physical features | No single physical pattern is established from the supplied data. | Variable physical features may be present; none are definitive alone. | Low |
When to favor each condition
Choose 3 Methylglutaconic Aciduria C3696376 when
Unexplained organic acid elevation
Supports metabolic evaluation rather than a chromosomal diagnosis.
High
Multisystem illness with neurologic change
Fits the described metabolic pattern, but confirmation is required.
Moderate
Need for metabolic support
Care emphasis is symptom management and metabolic support.
Moderate
Choose 17q11 2 Microduplication Syndrome C3495679 when
Suspected chromosomal duplication
The condition is defined by a 17q11.2 segment duplication.
High
Developmental and behavioral concerns
These features prompt genetic assessment, not a diagnosis alone.
Moderate
Need for early developmental support
Described management centers on early intervention.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria C3696376 | 17q11 2 Microduplication Syndrome C3495679 | Interpretation |
|---|---|---|---|
| Urine organic acids | May show 3-methylglutaconic acid elevation; cutoff not supplied. | No characteristic organic acid result is established. | An abnormal result is not itself a diagnosis. |
| Chromosomal microarray | Not the defining test from the supplied description. | May identify a 17q11.2 microduplication. | Genetic confirmation should be interpreted by a clinician. |
| Metabolic and neurologic assessment | May reveal variable multisystem or brain involvement. | May document developmental, behavioral, or physical findings. | Results guide evaluation but do not prove etiology alone. |
Prognosis comparison
3 Methylglutaconic Aciduria C3696376
- Outcome
- Chronic and potentially severe, with wide individual variation.
- Factors
- Extent of metabolic and neurologic involvement; exact outcomes are not established.
17q11 2 Microduplication Syndrome C3495679
- Outcome
- Generally described as moderate, but individual course varies.
- Factors
- Developmental, behavioral, and physical findings influence needs.
Time frame: Both are chronic; precise timelines are not supplied.
Confirmed diagnosis, complications, and access to supportive care.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic complications | Brain involvement is described and may be severe. Developmental delay may occur; severity is variable. Neither pattern is universal from the available data. |
| Metabolic instability | Abnormal acid buildup may affect multiple systems. Not described as a primary metabolic complication. Exact triggers and laboratory thresholds are not established here. |
| Behavioral and functional difficulties | Possible when neurologic disease is present. Behavioral concerns are part of the described phenotype. Support needs should be individualized. |
Patient education highlights
- HighDifferent causes
One is a metabolic disorder; the other is a chromosomal duplication. They are not interchangeable diagnoses.
- HighTest meaning
An abnormal laboratory or genetic result needs clinician interpretation and confirmatory context.
- MediumSupportive care
Care may include metabolic support or early developmental intervention, tailored to the confirmed condition.